Sygnature Discovery Announces Research Partnership with Daewoong Pharma
The partnership will allow Sygnature Discovery to provide virtual high throughput screening expertise, among other services, to Daewoong Pharma's projects.
Global integrated drug discovery company, Sygnature Discovery and global healthcare group Daewoong Pharmaceutical, have entered into a research collaboration agreement to accelerate the discovery of a novel small molecule to target autoimmune disease.
Sygnature Discovery will provide integrated drug discovery support using specialist fragment-based drug discovery (FBDD) and virtual high throughput screening (vHTS) expertise from its medicinal chemistry, biology, and computational science teams. The company will also support protein science and crystallography to accelerate novel drug discovery for Daewoong’s project.
Read more about this story here.
New machine-learning approach could speed precision drug development
The approach, detailed this week in the journal Nature, uses a platform called Molecular Surface Interaction Fingerprinting (MaSIF) to design custom proteins that bind to drug-bound target proteins.
AI-enabled CGM app shows promise for glycemic control, weight management
The broader implications of this study suggest that digital health platforms like January V2 have the potential to play a crucial role in the future of chronic disease management,” the authors write.
